Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacovigilance01:19

Pharmacovigilance

1.9K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.9K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

519
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
519
Methods of Documentation VI: Case Management Model01:15

Methods of Documentation VI: Case Management Model

999
The case management model is a multidisciplinary approach that involves healthcare professionals from diverse disciplines, such as physicians, nurses, therapists, social workers, and pharmacists, working collaboratively to address the various needs of patients. Each healthcare professional brings unique expertise and perspectives, contributing to a more comprehensive understanding of the patient's condition and tailoring treatment plans accordingly.
For example, a patient with a chronic...
999
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

59
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
59
Guidelines for Writing Outcome01:11

Guidelines for Writing Outcome

4.2K
When developing expected outcomes for a patient care plan, the nurse should adhere to the following recommendations:
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
4.2K
Drug Regulation01:25

Drug Regulation

3.2K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Filling the mechanistic and methodological gaps for predicting cytokine release syndrome in humans.

Frontiers in pharmacology·2026
Same author

Stakeholder input towards further refinement and consolidation of the alternative safety profiling algorithm (ASPA) for next generation risk assessment (NGRA).

ALTEX·2026
Same author

From concept to regulation: OECD's role in the development of the DNT <i>in vitro</i> battery.

Frontiers in toxicology·2026
Same author

Adverse Outcome Pathway (AOP) Coaching Program-how it functions and contributes to a more harmonized approach to AOP development and construction of AOP networks with regulatory utility.

Environmental toxicology and chemistry·2025
Same author

Developmental neurotoxicity (DNT): A call for implementation of new approach methodologies for regulatory purposes: Summary of the 5th International Conference on DNT Testing.

ALTEX·2025
Same author

Building an Adverse Outcome Pathway network for COVID-19.

Frontiers in systems biology·2025

Related Experiment Video

Updated: Mar 12, 2026

A Web Tool for Generating High Quality Machine-readable Biological Pathways
08:01

A Web Tool for Generating High Quality Machine-readable Biological Pathways

Published on: February 8, 2017

18.6K

The adverse outcome pathway concept: A basis for developing regulatory decision-making tools.

Nathalie Delrue1, Magdalini Sachana1, Yuki Sakuratani1

  • 1Organisation for Economic Co-operation and Development (OECD), Paris, France.

Alternatives to Laboratory Animals : ATLA
|November 3, 2016
PubMed
Summary

The Adverse Outcome Pathway (AOP) framework guides chemical risk assessment and the development of alternative testing strategies. This approach aims to reduce animal testing by utilizing existing data and developing new in vitro methods.

More Related Videos

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

1.1K
A Pathway Association Study Tool for GWAS Analyses of Metabolic Pathway Information
05:01

A Pathway Association Study Tool for GWAS Analyses of Metabolic Pathway Information

Published on: July 1, 2020

3.8K

Related Experiment Videos

Last Updated: Mar 12, 2026

A Web Tool for Generating High Quality Machine-readable Biological Pathways
08:01

A Web Tool for Generating High Quality Machine-readable Biological Pathways

Published on: February 8, 2017

18.6K
Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

1.1K
A Pathway Association Study Tool for GWAS Analyses of Metabolic Pathway Information
05:01

A Pathway Association Study Tool for GWAS Analyses of Metabolic Pathway Information

Published on: July 1, 2020

3.8K

Area of Science:

  • Toxicology
  • Chemical Safety Assessment
  • Regulatory Science

Background:

  • The Adverse Outcome Pathway (AOP) concept provides a framework for understanding chemical toxicity.
  • AOPs are crucial for guiding risk assessors and targeting data generation for regulatory purposes.
  • The Organisation for Economic Co-operation and Development (OECD) utilizes AOPs in its chemical safety program.

Purpose of the Study:

  • To demonstrate the utility of AOPs in developing alternative methods for hazard assessment.
  • To support the replacement of animal testing through innovative strategies.
  • To implement AOPs within regulatory frameworks for chemical safety.

Main Methods:

  • Development and implementation of an AOP for skin sensitization as a proof-of-concept.
  • Integration of the skin sensitization AOP into the OECD QSAR Toolbox for chemical grouping.
  • Development of alternative in vitro test methods targeting Key Events (KEs) within the AOP.

Main Results:

  • Successful implementation of a skin sensitization AOP into the OECD QSAR Toolbox.
  • Development of alternative test methods for KEs, enabling animal-free testing for skin sensitization.
  • Establishment of an AOP development program with an initial batch of AOPs published in 2016.

Conclusions:

  • AOPs are effective in guiding the development of alternative testing strategies and reducing animal use.
  • The OECD AOP program is advancing the use of AOPs and supporting IT tools like the AOP Knowledge Base.
  • Future regulatory use of AOPs will be prioritized by OECD member countries to enhance chemical safety assessment.